About the Problem Statement:

Teijin Pharma Limited (Teijin) is looking for solutions for the ageing population to correctly understand their own health conditions.

Startups with capabilities to develop AI algorithms based on health / vital data for chronic diseases and startups with technologies for sensing vital signals for chronic diseases would be relevant.

Objectives:

To provide an easy solution for the ageing population with chronic diseases to proactively understand their own health conditions from the patients’ homes. This includes, but should not be limited to, innovative technology to predict exacerbation before their illness gets worse.

Working Model:

Teijin is open to discussing the collaboration model with startups but typically takes responsibility for technology development for the Japanese market, conducting clinical studies, regulatory / reimbursement tasks and finally commercialisation in Japan.

To achieve the goal, Teijin will invest with dilutive (equity) and/or non-dilutive funding in the partner(s).